Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
-0.27%63.771.4%$1739.02m
JNJJohnson & Johnson
0.07%141.440.7%$876.14m
PFEPfizer Inc.
-0.55%38.330.9%$729.42m
MRKMerck & Co., Inc.
0.32%89.240.7%$685.29m
ABBVAbbVie, Inc.
-1.07%87.782.3%$607.65m
LLYEli Lilly & Co.
-0.14%121.531.1%$364.17m
NVSNovartis AG
0.25%93.290.2%$151.08m
AZNAstraZeneca Plc
0.92%48.361.2%$138.40m
GSKGlaxoSmithKline Plc
0.13%45.990.2%$137.93m
SNYSanofi
0.57%49.790.2%$114.51m
RETAReata Pharmaceuticals, Inc.
2.84%206.753.5%$108.66m
KRTXKaruna Therapeutics, Inc.
-11.24%65.250.0%$105.65m
NVONovo Nordisk A/S
1.33%57.250.1%$92.18m
ALLKAllakos, Inc.
-2.21%123.190.0%$74.02m
FTSVForty Seven, Inc.
-7.72%35.750.0%$50.91m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.